On March 3, 2023 Immune-Onc Therapeutics, Inc. ("Immune-Onc"), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, announced today its plans to present on the company’s myeloid biology research and clinical stage programs at three upcoming scientific and investor conferences in March. The presentations will highlight the potential of Immune-Onc’s pipeline of first-in-class myeloid checkpoint inhibitors to transform current treatment approaches for blood cancers and solid tumors.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Keystone Symposia: Cancer Immunotherapy: Mechanisms of Response Versus Resistance
Date: Sunday, March 5 – Thursday, March 9
Location: Alberta, Canada
At the prestigious Keystone Symposia on Cancer Immunotherapy, Immune-Onc’s Scientific Founder Dr. Chengcheng Alec Zhang will join the company’s Chair of the Scientific Advisory Board (SAB), Dr. Michael Karin and Senior Director of Translational Research, Dr. Xiao Min Schebye for a series of pivotal presentations highlighting foundational research and insights driving our evolving understanding of mechanisms of response and resistance to cancer immunotherapy, and in particular, the LILRB family of immune inhibitory receptors as a promising class of therapeutic targets.
Oral Presentation Details:
Date: Monday, March 6
Presenter: Dr. Michael Karin, Immune-Onc SAB chair and professor of pharmacology at University of California, San Diego
Title: Inflammation and Cancer: A Double-Edged Sword
Oral Session: Dysfunctional Immune Cells in the TME
Date: Wednesday, March 8
Presenter: Dr. Xiao Min Schebye, senior director of translational research at Immune-Onc
Title: Anti-LAIR1 Antagonistic Antibodies Block Collagen-mediated Suppression of T Cell Activation
Oral Session: Workshop 2
Date: Wednesday, March 8
Presenter: Dr. Chengcheng Alec Zhang, scientific founder of Immune-Onc and the Morton H. Sanger Professorship in Oncology and Michael L. Rosenberg Scholar for Biomedical Research at University of Texas Southwestern Medical Center
Title: LILRBs – Myeloid Checkpoint Targets for Cancer Treatment
Oral Session: Innate Immune Pathways and the Anti-Tumor Response
2nd Year Anniversary Symposium of the Myeloid Network
Date: Thursday, March 9 from 11:00 a.m. – 2:30 p.m. ET
Title: Novel Myeloid Checkpoint Inhibitors as Next Generation Cancer Immunotherapy
Location: Virtual
Charlene Liao, Ph.D., founder, chief executive officer and board chair of Immune-Onc will present an overview of the company’s work advancing the field of myeloid checkpoint inhibitors at the 2nd Year Anniversary Symposium of the Myeloid Network. The Myeloid Network seeks to connect researchers worldwide to promote communication and advancement of research and medicine in the field of myeloid cell biology. "I think your work represents the biotechnology industry outstandingly and I would love to feature your work as the final talk of our annual symposium," said Judith Varner, Ph.D., co-founder of the Myeloid Network, professor of pathology and medicine and co-leader in solid tumor therapeutics at UC San Diego’s Moores Cancer Center in the invitation extended to Dr. Liao.
Oppenheimer 33rd Annual Healthcare Conference
Date: Monday, March 13 – Wednesday, March 15
Presentation: Tuesday, March 14 (4:00-4:30 p.m. ET)
Dr. Liao will present a corporate overview on Tuesday, March 14 at 4:00 – 4:30 p.m. ET (Track 2) and will participate in virtual one-on-one meetings.